A randomized phase II study of cisplatin+TS-1 versus cisplatin+docetaxel, with thoracic radiotherapy for locally advanced non-small cell lung cancer (TORG1018)
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000005993
- Lead Sponsor
- Thoracic Oncology Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 110
Not provided
1)T3N1 2)SVC syndrome with difficulty of a lot of intravenous infusion 3)clinically significant contralateral hilar lymph node metastasis, carcinomatous pericardial or pleural effusion, or carcinomatous lymphangitis 4)concurent serious infection or complications 5)continuous watery diarrhea 6)significant interstitial pneumonitis or pulmonary fibrosis in chest CT 7)concomitant cancers within 5 years 8)concomitant therapy with another new anticancer drug, phenytoin, warfarin or flucytocine 9)inadequately controlled diabetes mellitus 10)HBs Ag is positive 11)a history of serious drug allergy 12)mental disease or psychotic manifestation 13)pregnancy, breast feeding, wish of future bearing or hesitation in contraception 14)other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2 year survival rate
- Secondary Outcome Measures
Name Time Method over all survival, progression free survival, adverse events, dose intensity